In 2014, nivolumab (OPDIVO, Bristol-Myers Squibb Company), an anti-PD-1 mAb was approved by the FDA for melanoma patients and marked the start of several other approvals in other cancer types. The gene discussed is PDCD1; the disease is cancer.